Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04607668 · ClinicalTrials.gov registry record · Phase 3
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
A Phase 3 study, sponsored by G1 Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT04607668 is a Phase 3 study that was terminated before completion, run by G1 Therapeutics. The registered enrollment target is 326 participants.
The verdict
NCT04607668, a Phase 3 study, was terminated before completion, sponsored by G1 Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in patients with pMMR/MSS mCRC who have not received systemic therapy for metastatic disease.
Interventions
- DRUG Placebo
- DRUG Trilaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04607668
The ClinicalTrials.gov registry entry for NCT04607668 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is G1 Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04607668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04607668 about?
NCT04607668 is a clinical study titled "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):". This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in patients with pMMR/MSS mCRC who have not received systemic therapy for met...
What is the current status of trial NCT04607668?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2021-01-06. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT04607668?
The interventions under investigation include: Placebo (DRUG), Trilaciclib (DRUG).
Who is sponsoring clinical trial NCT04607668?
This trial is sponsored by G1 Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.